[Pharmacokinetics of cisplatin and vindesine in a patient with chronic renal failure undergoing hemodialysis]. 1989

H Ayabe, and T Uchikawa, and K Kimino, and Y Tagawa, and K Kawahara, and M Tomita
First Dept. of Surgery, Nagasaki University Hospital.

Plasma total platinum and vindesine levels were monitored in a patient with chronic renal failure undergoing hemodialysis. Plasma levels of cisplatin were determined as platinum by atomic absorption spectrophotometry, and plasma vindesine levels were measured by radioimmunoassay. Fifty mg. of cisplatin in combination with 3 mg. of vindesine were infused for 60 minutes before dialysis. During dialysis, plasma total platinum levels decreased rapidly in a biphasic fashion and 1.76 at 30 hours after infusion. Plasma vindesine levels declined with higher concentration. In conclusion, it is considered that cisplatin and vindesine can be given to anuric patients undergoing hemodialysis. However, it is suggested that smaller doses should be given to prevent side effects.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D014751 Vindesine Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS). Compound 112531,Desacetylvinblastine Amide,Eldisine,Enison,NSC-245467,Vindesin,Vindesine Sulfate,NSC 245467,NSC245467,Sulfate, Vindesine

Related Publications

H Ayabe, and T Uchikawa, and K Kimino, and Y Tagawa, and K Kawahara, and M Tomita
December 2013, Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India,
H Ayabe, and T Uchikawa, and K Kimino, and Y Tagawa, and K Kawahara, and M Tomita
April 2008, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
H Ayabe, and T Uchikawa, and K Kimino, and Y Tagawa, and K Kawahara, and M Tomita
November 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
H Ayabe, and T Uchikawa, and K Kimino, and Y Tagawa, and K Kawahara, and M Tomita
October 2001, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
H Ayabe, and T Uchikawa, and K Kimino, and Y Tagawa, and K Kawahara, and M Tomita
January 1979, Therapie,
H Ayabe, and T Uchikawa, and K Kimino, and Y Tagawa, and K Kawahara, and M Tomita
October 1983, Antimicrobial agents and chemotherapy,
H Ayabe, and T Uchikawa, and K Kimino, and Y Tagawa, and K Kawahara, and M Tomita
August 1983, The Journal of infectious diseases,
H Ayabe, and T Uchikawa, and K Kimino, and Y Tagawa, and K Kawahara, and M Tomita
September 2011, Esophagus : official journal of the Japan Esophageal Society,
H Ayabe, and T Uchikawa, and K Kimino, and Y Tagawa, and K Kawahara, and M Tomita
January 2010, Anais brasileiros de dermatologia,
H Ayabe, and T Uchikawa, and K Kimino, and Y Tagawa, and K Kawahara, and M Tomita
April 2002, Annals of nuclear medicine,
Copied contents to your clipboard!